Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus signs development contract with Galapagos
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos’s Phase II study of Nanocort. OctoPlus said that it has progressed the scale-up and robustness of
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos’s Phase II study of Nanocort. OctoPlus said that it has progressed the scale-up and robustness of
Oscient said that the employees affected by the restructuring will be offered severance benefits. The company is also eliminating approximately 25 positions which have been vacant. Following the
Forty-seven medical centers ordered the company’s Proxcelan seeds in the second quarter of fiscal 2009 compared to the 53 centers that ordered in the first quarter of fiscal
For the second quarter of fiscal 2009, the company reported increased net revenue included product revenue of $8,061,000 for the second quarter of fiscal 2009, an 8.2% increase,
The decision was made based on the results of the Phase III study of maribavir in stem cell transplant patients, and the recommendation from the independent data monitoring
Mr Gallahue has successfully participated in a variety of financial transactions, including initial public offerings, mergers, joint ventures, private placements and follow-on offerings at a number of healthcare
Cardinal Health said that the new company will be named CareFusion, reflecting a diverse blend of medical technologies the company will offer to improve the safety and quality
Denver Health is receiving funding for the study as a team science award from the Colorado Clinical and Translational Sciences Institute. Accelr8 has provided analytical instrumentation to Denver
Monet1 is a Phase III study evaluating motesanib in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Motesanib is
The first clinical case was successfully performed by Karl-Heinz Kuck, director of the cardiologic center at the Asklepios Klinik in Hamburg, Germany, said Biotronik. During this case a